focus -WSS

focus

author：leisure time 2025-08-12 06:44:17 - browse：58

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Sanofi says it has 12 blockbusters on the way. Will investors believe it?

WSS

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

FDA approves world's first CRISPR

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

FDA needs staff influx to meet gene therapy needs, Marks says

Patients' immediate access to test results puts radiologists in a bind

Digital health funding stays low as a new reality sets in

focus

focus

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

SCOTUS to consider access to abortion pill mifepristone

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

After half a century, Israel moves to evict squatter from his cave home on the beach

Virginia high school admissions case could be legal follow

Pregnancy discrimination could be enabled by AI

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

hotspot

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

The debate over Covid

Cuban government calls US nuclear submarine stop a 'provocative escalation'

What causes an itch? Researchers may have solved the mystery

How are insurers handling Leqembi and related scans?

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

entertainment

focus

focus

focus